Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Biogen Inc. (BIIB)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Biogen Inc..
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 875045.
Total stock buying since 2015: $183,154,843.
Total stock sales since 2015: $66,270,692.
Total stock option exercises since 2015: $8,498,226.
Table 3. Detailed insider trading at Biogen Inc. (BIIB) , Part 2
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2019-03-18 | Pangia Robert W (Director) | Sale | 6,114 | 328.55 | 2,008,754 |
| 2019-03-18 | Pangia Robert W (Director) | Option Ex | 6,114 | 52.22 | 319,273 |
| 2019-03-01 | Mckenzie Paul (EVP Pharmaceutical Oper & Tech) | Option Ex | 568 | .00 | 0 |
| 2019-02-15 | Mckenzie Paul (EVP Pharmaceutical Oper & Tech) | Option Ex | 1,448 | .00 | 0 |
| 2019-02-15 | Ehlers Michael D (EVP, Research and Development) | Option Ex | 1,685 | .00 | 0 |
| 2019-02-15 | Vounatsos Michel (Chief Executive Officer) | Option Ex | 5,269 | .00 | 0 |
| 2019-02-15 | Sandrock Alfred (EVP, Chief Medical Officer) | Option Ex | 1,318 | .00 | 0 |
| 2019-02-15 | Alexander Susan H (EVP Chief Legal Officer & Sec.) | Option Ex | 1,685 | .00 | 0 |
| 2019-02-12 | Mckenzie Paul (EVP Pharmaceutical Oper & Tech) | Option Ex | 3,062 | .00 | 0 |
| 2019-02-12 | Ehlers Michael D (EVP, Research and Development) | Option Ex | 3,827 | .00 | 0 |
| 2019-02-12 | Vounatsos Michel (Chief Executive Officer) | Option Ex | 6,899 | .00 | 0 |
| 2019-02-12 | Sandrock Alfred (EVP, Chief Medical Officer) | Option Ex | 4,643 | .00 | 0 |
| 2019-02-12 | Gregory Ginger (EVP, Human Resources) | Option Ex | 1,836 | .00 | 0 |
| 2019-02-12 | Alexander Susan H (EVP Chief Legal Officer & Sec.) | Option Ex | 3,268 | .00 | 0 |
| 2019-02-01 | Denner Alexander J (Director) | Buy | 7,000 | 328.45 | 2,299,164 |
| 2019-01-31 | Denner Alexander J (Director) | Buy | 25,800 | 330.52 | 8,527,390 |
| 2019-01-30 | Denner Alexander J (Director) | Buy | 30,000 | 324.86 | 9,745,860 |
| 2019-01-02 | Capello Jeffrey D (EVP & Chief Financial Officer) | Option Ex | 1,331 | .00 | 0 |
| 2018-12-01 | Guindo Chirfi (EVP Glob. Mkt Acc & Cust Innov) | Option Ex | 602 | .00 | 0 |
| 2018-09-26 | Ehlers Michael D (EVP, Research and Development) | Sale | 1,000 | 350.00 | 350,000 |
| 2018-08-01 | Gregory Ginger (EVP, Human Resources) | Option Ex | 262 | .00 | 0 |
| 2018-06-01 | Ehlers Michael D (EVP, Research and Development) | Option Ex | 1,384 | .00 | 0 |
| 2018-05-02 | Vounatsos Michel (Chief Executive Officer) | Option Ex | 1,687 | .00 | 0 |
| 2018-04-25 | Denner Alexander J (Director) | Buy | 48,000 | 269.91 | 12,955,680 |
| 2018-03-01 | Mckenzie Paul (EVP Pharmaceutical Oper & Tech) | Option Ex | 532 | .00 | 0 |
| 2018-02-27 | Sandrock Alfred (EVP, Chief Medical Officer) | Sale | 259 | 290.83 | 75,324 |
| 2018-02-23 | Sandrock Alfred (EVP, Chief Medical Officer) | Sale | 908 | 293.44 | 266,443 |
| 2018-02-23 | Sandrock Alfred (EVP, Chief Medical Officer) | Option Ex | 467 | .00 | 0 |
| 2018-02-23 | Alexander Susan H (EVP Chief Legal Corp Svc & Sec) | Option Ex | 857 | .00 | 0 |
| 2018-02-23 | Covino Gregory F (VP, Chief Accounting Officer) | Option Ex | 92 | .00 | 0 |
| 2018-02-22 | Sandrock Alfred (EVP, Chief Medical Officer) | Option Ex | 1,635 | .00 | 0 |
| 2018-02-22 | Covino Gregory F (VP, Chief Accounting Officer) | Option Ex | 194 | .00 | 0 |
| 2018-02-20 | Sandrock Alfred (EVP, Chief Medical Officer) | Sale | 743 | 292.00 | 216,956 |
| 2018-02-15 | Mckenzie Paul (EVP Pharmaceutical Oper & Tech) | Option Ex | 1,472 | .00 | 0 |
| 2018-02-15 | Ehlers Michael D (EVP, Research and Development) | Option Ex | 1,712 | .00 | 0 |
| 2018-02-15 | Vounatsos Michel (Chief Executive Officer) | Option Ex | 5,354 | .00 | 0 |
| 2018-02-15 | Sandrock Alfred (EVP, Chief Medical Officer) | Sale | 1,294 | 298.85 | 386,711 |
| 2018-02-15 | Sandrock Alfred (EVP, Chief Medical Officer) | Option Ex | 1,339 | .00 | 0 |
| 2018-02-15 | Alexander Susan H (EVP Chief Legal Corp Svc & Sec) | Option Ex | 1,712 | .00 | 0 |
| 2018-02-15 | Covino Gregory F (VP, Chief Accounting Officer) | Option Ex | 161 | .00 | 0 |
| 2018-02-12 | Sandrock Alfred (EVP, Chief Medical Officer) | Option Ex | 2,012 | .00 | 0 |
| 2018-01-09 | Pangia Robert W (Director) | Sale | 5,832 | 329.65 | 1,922,518 |
| 2018-01-09 | Pangia Robert W (Director) | Option Ex | 5,832 | 57.83 | 337,264 |
| 2017-12-29 | Vounatsos Michel (Chief Executive Officer) | Buy | 780 | 320.55 | 250,029 |
| 2017-11-29 | Denner Alexander J (Director) | Buy | 10,000 | 319.84 | 3,198,399 |
| 2017-11-28 | Denner Alexander J (Director) | Buy | 20,000 | 316.12 | 6,322,400 |
| 2017-07-25 | Alexander Susan H (EVP Chief Legal Corp Svc & Sec) | Sale | 4,974 | 290.01 | 1,442,509 |
| 2017-07-19 | Alexander Susan H (EVP Chief Legal Corp Svc & Sec) | Sale | 7,758 | 285.00 | 2,211,030 |
| 2017-06-09 | Posner Brian S (Director) | Sale | 1,084 | 256.31 | 277,840 |
| 2017-06-01 | Ehlers Michael D (EVP, Research and Development) | Option Ex | 1,259 | .00 | 0 |
| 2017-05-02 | Vounatsos Michel (Chief Executive Officer) | Option Ex | 1,736 | .00 | 0 |
| 2017-05-01 | Vounatsos Michel (Chief Executive Officer) | Buy | 1,402 | 271.35 | 380,432 |
| 2017-04-27 | Denner Alexander J (Director) | Buy | 73,858 | 278.53 | 20,571,668 |
| 2017-04-25 | Clancy Paul J (Executive VP and CFO) | Sale | 9,892 | 290.00 | 2,868,680 |
| 2017-04-03 | Sandrock Alfred (EVP CMO Neuro & Neurodegenerat) | Sale | 1,981 | 274.08 | 542,952 |
| 2017-03-13 | Clancy Paul J (Executive VP and CFO) | Sale | 9,891 | 291.55 | 2,883,721 |
| 2017-03-01 | Mckenzie Paul (EVP Pharmaceutical Oper & Tech) | Option Ex | 481 | .00 | 0 |
| 2017-03-01 | Sandrock Alfred (EVP CMO Neuro & Neurodegenerat) | Sale | 973 | 290.07 | 282,238 |
| 2017-02-28 | Karaboutis Adriana (EVP, Tech, Bus. Sol & Corp Aff) | Option Ex | 2,064 | .00 | 0 |
| 2017-02-28 | Sandrock Alfred (EVP CMO Neuro & Neurodegenerat) | Option Ex | 4,785 | .00 | 0 |
| 2017-02-28 | Dipietro Kenneth (EVP Human Resources) | Option Ex | 5,696 | .00 | 0 |
| 2017-02-28 | Clancy Paul J (Executive VP and CFO) | Option Ex | 6,780 | .00 | 0 |
| 2017-02-28 | Alexander Susan H (EVP, Chief Legal Officer) | Option Ex | 5,559 | .00 | 0 |
| 2017-02-28 | Covino Gregory F (VP, Chief Accounting Officer) | Option Ex | 681 | .00 | 0 |
| 2017-02-27 | Vounatsos Michel (Chief Executive Officer) | Buy | 1,333 | 285.39 | 380,424 |
| 2017-01-09 | Pangia Robert W (Director) | Sale | 5,450 | 295.39 | 1,609,875 |
| 2017-01-09 | Pangia Robert W (Director) | Option Ex | 5,450 | 52.22 | 284,599 |
| 2016-10-04 | Karaboutis Adriana (EVP, Tech, Bus. Sol & Corp Aff) | Sale | 262 | 311.94 | 81,728 |
| 2016-10-03 | Karaboutis Adriana (EVP, Tech, Bus. Sol & Corp Aff) | Sale | 380 | 313.00 | 118,940 |
| 2016-10-01 | Karaboutis Adriana (EVP, Tech, Bus. Sol & Corp Aff) | Option Ex | 1,982 | .00 | 0 |
| 2016-09-22 | Dorsa Caroline (Director) | Sale | 27,570 | 314.00 | 8,656,980 |
| 2016-09-22 | Dorsa Caroline (Director) | Option Ex | 27,570 | 53.64 | 1,478,854 |
| 2016-07-21 | Scangos George A (Chief Executive Officer) | Sale | 157 | 280.00 | 43,960 |
| 2016-06-06 | Koppel Adam (EVP, Strategy and Bus. Dev.) | Sale | 555 | 290.00 | 160,950 |
| 2016-06-03 | Scangos George A (Chief Executive Officer) | Sale | 842 | 290.00 | 244,180 |
| 2016-06-02 | Koppel Adam (EVP, Strategy and Bus. Dev.) | Option Ex | 1,643 | .00 | 0 |
| 2016-06-01 | Scangos George A (Chief Executive Officer) | Sale | 487 | 287.97 | 140,241 |
| 2016-05-31 | Scangos George A (Chief Executive Officer) | Sale | 3,368 | 290.00 | 976,720 |
| 2016-05-25 | Scangos George A (Chief Executive Officer) | Sale | 157 | 280.00 | 43,960 |
| 2016-05-02 | Scangos George A (Chief Executive Officer) | Sale | 487 | 274.74 | 133,798 |
| 2016-05-01 | Covino Gregory F (VP, Chief Accounting Officer) | Option Ex | 348 | .00 | 0 |
| 2016-04-06 | Koppel Adam (EVP, Strategy and Bus. Dev.) | Sale | 102 | 275.00 | 28,050 |
| 2016-04-06 | Scangos George A (Chief Executive Officer) | Sale | 157 | 280.00 | 43,960 |
| 2016-04-02 | Artavanis-tsakonas Spyridon (EVP, Chief Scientific Officer) | Option Ex | 975 | .00 | 0 |
| 2016-04-01 | Scangos George A (Chief Executive Officer) | Sale | 487 | 258.83 | 126,050 |
| 2016-02-17 | Scangos George A (Chief Executive Officer) | Sale | 487 | 256.16 | 124,749 |
| 2016-02-12 | Artavanis-tsakonas Spyridon (SVP, Chief Scientific Officer) | Option Ex | 1,057 | .00 | 0 |
| 2016-02-12 | Clancy Paul J (Executive VP and CFO) | Option Ex | 3,859 | .00 | 0 |
| 2016-02-09 | Sandrock Alfred (EVP CMO Neuro & Neurodegenerat) | Sale | 852 | 246.54 | 210,052 |
| 2016-02-09 | Scangos George A (Chief Executive Officer) | Option Ex | 11,274 | .00 | 0 |
| 2016-02-08 | Sandrock Alfred (EVP CMO Neuro & Neurodegenerat) | Option Ex | 1,278 | .00 | 0 |
| 2016-02-08 | Cox John (EVP Pharmaceutical Oper & Tech) | Option Ex | 4,026 | .00 | 0 |
| 2016-02-01 | Dipietro Kenneth (EVP Human Resources) | Option Ex | 2,466 | 273.45 | 674,327 |
| 2015-12-04 | Sandrock Alfred (EVP CMO Neuro & Neurodegenerat) | Sale | 441 | 277.00 | 122,157 |
| 2015-12-02 | Karaboutis Adriana (EVP, Tech. and Bus. Solutions) | Sale | 48 | 289.14 | 13,878 |
| 2015-10-23 | Denner Alexander J (Director) | Buy | 100,000 | 276.77 | 27,677,000 |
| 2015-10-22 | Denner Alexander J (Director) | Buy | 210,000 | 277.80 | 58,338,000 |
| 2015-10-05 | Karaboutis Adriana (EVP, Tech. and Bus. Solutions) | Sale | 269 | 291.43 | 78,394 |
| 2015-10-02 | Karaboutis Adriana (EVP, Tech. and Bus. Solutions) | Sale | 417 | 283.38 | 118,169 |
| 2015-10-01 | Karaboutis Adriana (EVP, Tech. and Bus. Solutions) | Option Ex | 1,939 | .00 | 0 |
| 2015-07-27 | Papadopoulos Stelios (Director) | Buy | 10,000 | 304.88 | 3,048,780 |
| 2015-06-22 | Posner Brian S (Director) | Sale | 470 | 415.00 | 195,050 |
| 2015-06-19 | Williams Douglas E (EVP Research & Development) | Sale | 3,841 | 410.00 | 1,574,810 |
| 2015-06-15 | Posner Brian S (Director) | Sale | 400 | 386.64 | 154,656 |
| 2015-06-02 | Koppel Adam (SVP, Chief Strategy Officer) | Option Ex | 2,384 | .00 | 0 |
| 2015-06-01 | Scangos George A (Chief Executive Officer) | Sale | 1,362 | 398.87 | 543,260 |
| 2015-05-01 | Covino Gregory F (VP, Chief Accounting Officer) | Option Ex | 347 | 386.22 | 134,018 |
| 2015-04-02 | Artavanis-tsakonas Spyridon (SVP, Chief Scientific Officer) | Option Ex | 975 | .00 | 0 |
| 2015-04-01 | Scangos George A (Chief Executive Officer) | Sale | 1,362 | 423.20 | 576,398 |
| 2015-03-27 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Sale | 430 | 430.12 | 184,951 |
| 2015-03-25 | Cox John (EVP Pharmaceutical Oper & Tech) | Sale | 12,010 | 449.06 | 5,393,210 |
| 2015-03-25 | Cox John (EVP Pharmaceutical Oper & Tech) | Option Ex | 5,066 | 66.72 | 337,978 |
| 2015-03-20 | Rowinsky Eric K (Director) | Sale | 11,667 | 475.00 | 5,541,825 |
| 2015-03-20 | Rowinsky Eric K (Director) | Option Ex | 11,667 | 59.82 | 697,919 |
| 2015-03-19 | Rowinsky Eric K (Director) | Sale | 2,333 | 436.14 | 1,017,507 |
| 2015-03-19 | Rowinsky Eric K (Director) | Option Ex | 2,333 | 59.82 | 139,560 |
| 2015-03-17 | Rowinsky Eric K (Director) | Sale | 4,667 | 425.45 | 1,985,589 |
| 2015-03-17 | Rowinsky Eric K (Director) | Option Ex | 4,667 | 59.82 | 279,179 |
| 2015-03-16 | Dipietro Kenneth (EVP Human Resources) | Sale | 803 | 415.46 | 333,614 |
| 2015-03-13 | Scangos George A (Chief Executive Officer) | Sale | 537 | 412.69 | 221,613 |
| 2015-03-10 | Pangia Robert W (Director) | Sale | 3,625 | 413.23 | 1,497,958 |
| 2015-03-10 | Pangia Robert W (Director) | Option Ex | 3,625 | 49.60 | 179,818 |
| 2015-03-10 | Sherwin Stephen A (Director) | Sale | 6,000 | 409.67 | 2,458,020 |
| 2015-03-10 | Sherwin Stephen A (Director) | Option Ex | 6,000 | 59.82 | 358,920 |
| 2015-03-09 | Rowinsky Eric K (Director) | Sale | 4,666 | 417.23 | 1,946,795 |
| 2015-03-09 | Rowinsky Eric K (Director) | Option Ex | 4,666 | 59.82 | 279,120 |
| 2015-03-02 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Sale | 3,174 | 409.06 | 1,298,350 |
| 2015-03-02 | Scangos George A (Chief Executive Officer) | Sale | 825 | 410.67 | 338,802 |
| 2015-02-19 | Scangos George A (Chief Executive Officer) | Sale | 537 | 401.04 | 215,358 |
| 2015-02-17 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Sale | 418 | 389.11 | 162,647 |
| 2015-02-17 | Dipietro Kenneth (EVP Human Resources) | Sale | 1,188 | 389.11 | 462,262 |
| 2015-02-17 | Holtzman Steven H (EVP Corporate Development) | Sale | 2,128 | 389.11 | 828,026 |
| 2015-02-17 | Scangos George A (Chief Executive Officer) | Sale | 825 | 389.11 | 321,015 |
| 2015-02-12 | Artavanis-tsakonas Spyridon (SVP, Chief Scientific Officer) | Option Ex | 1,201 | .00 | 0 |
| 2015-02-12 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Option Ex | 1,605 | .00 | 0 |
| 2015-02-12 | Dipietro Kenneth (EVP Human Resources) | Option Ex | 3,764 | .00 | 0 |
| 2015-02-12 | Cox John (EVP Pharmaceutical Oper & Tech) | Option Ex | 3,738 | .00 | 0 |
| 2015-02-12 | Clancy Paul J (Executive VP and CFO) | Option Ex | 4,299 | .00 | 0 |
| 2015-02-12 | Kingsley Stuart A (EVP, Global Comm. Operations) | Option Ex | 3,601 | .00 | 0 |
| 2015-02-12 | Holtzman Steven H (EVP Corporate Development) | Option Ex | 3,634 | .00 | 0 |
| 2015-02-12 | Alexander Susan H (EVP, Chief Legal Officer) | Option Ex | 3,769 | .00 | 0 |
| 2015-02-12 | Covino Gregory F (VP, Chief Accounting Officer) | Option Ex | 471 | .00 | 0 |
| 2015-02-12 | Scangos George A (Chief Executive Officer) | Option Ex | 15,599 | .00 | 0 |
| 2015-02-12 | Williams Douglas E (EVP Research & Development) | Option Ex | 5,200 | .00 | 0 |
| 2015-02-10 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Sale | 1,143 | 398.63 | 455,630 |
| 2015-02-10 | Scangos George A (Chief Executive Officer) | Option Ex | 18,833 | .00 | 0 |
| 2015-02-09 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Sale | 856 | 398.05 | 340,730 |
| 2015-02-09 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Option Ex | 1,824 | .00 | 0 |
| 2015-02-09 | Cox John (EVP Pharmaceutical Oper & Tech) | Option Ex | 4,691 | .00 | 0 |
| 2015-02-09 | Clancy Paul J (Executive VP and CFO) | Option Ex | 4,691 | .00 | 0 |
| 2015-02-09 | Kingsley Stuart A (EVP, Global Comm. Operations) | Option Ex | 1,824 | .00 | 0 |
| 2015-02-09 | Alexander Susan H (EVP, Chief Legal Officer) | Option Ex | 3,909 | .00 | 0 |
| 2015-02-09 | Scangos George A (Chief Executive Officer) | Option Ex | 11,270 | .00 | 0 |
| 2015-02-08 | Sandrock Alfred (Grp SVP, Chief Medical Officer) | Option Ex | 1,277 | .00 | 0 |
| 2015-02-08 | Cox John (EVP Pharmaceutical Oper & Tech) | Option Ex | 4,023 | .00 | 0 |
| 2015-02-08 | Clancy Paul J (Executive VP and CFO) | Option Ex | 3,191 | .00 | 0 |
| 2015-02-08 | Kingsley Stuart A (EVP, Global Comm. Operations) | Option Ex | 2,636 | .00 | 0 |
| 2015-02-08 | Holtzman Steven H (EVP Corporate Development) | Option Ex | 2,705 | .00 | 0 |
| 2015-02-08 | Alexander Susan H (EVP, Chief Legal Officer) | Option Ex | 2,498 | .00 | 0 |
| 2015-02-08 | Williams Douglas E (EVP Research & Development) | Option Ex | 3,468 | .00 | 0 |
| 2015-02-02 | Dipietro Kenneth (EVP Human Resources) | Sale | 1,656 | 389.03 | 644,233 |
| 2015-02-01 | Dipietro Kenneth (EVP Human Resources) | Option Ex | 2,463 | .00 | 0 |
| 2015-02-01 | Holtzman Steven H (EVP Corporate Development) | Option Ex | 5,157 | .00 | 0 |
| 2015-02-01 | Williams Douglas E (EVP Research & Development) | Option Ex | 5,157 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
of BIIB listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Biogen Inc. (symbol BIIB,
CIK number 875045) see
the Securities and Exchange Commission (SEC) website.